Leaflet CARBOPLATIN KABI 10mg / ml concentrate for solution for infusion


Indicated for: cancer

Route of administration: infusion

Substance: carboplatin (antineoplastic agent)

ATC: L01XA02 (Antineoplastic and immunomodulating agents | Other antineoplastic agents | Platinum compounds)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Nephrotoxicity
Nephrotoxicity

This medicine may affect the kidneys.

Ototoxicity
Ototoxicity

This medicine may affect hearing or balance.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Carboplatin is a chemotherapy medication used to treat various types of cancer, including ovarian, lung, bladder, and breast cancer. It belongs to the class of platinum-based compounds and works by interfering with the DNA of cancer cells, inhibiting their division and growth.

Carboplatin is administered intravenously, usually in cycles, and the dosage is adjusted based on the patient's weight, kidney function, and the type of cancer being treated. It is often used in combination with other chemotherapy drugs to enhance treatment effectiveness.

Patients need to be closely monitored during treatment to detect potential side effects, such as a decrease in blood cell counts, nausea, or kidney toxicity. It is important to strictly follow the doctor's instructions.

Common side effects include fatigue, nausea, vomiting, loss of appetite, and an increased risk of infections. In rare cases, severe allergic reactions or hearing loss may occur. Patients should inform their doctor of any unusual symptoms.

General data about CARBOPLATIN KABI 10mg / ml

  • Substance: carboplatin
  • Date of last drug list: 01-06-2026
  • Commercial code: W65006002
  • Concentration: 10mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: generic
  • Price: 104.90 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: FRESENIUS KABI ONCOLOGY PLC - MAREA BRITANIE
  • Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA
  • Number: 10718/2018/02
  • Shelf life: 2 years-dupa ambalarea pt.comercializare;dupa diluare - it is used immediately

Pharmaceutical forms available for carboplatin

Concentrations available for carboplatin

  • 10mg/ml
  • 150mg
  • 150mg/15ml
  • 450mg
  • 450mg/45ml
  • 50mg
  • 50mg/5ml

Compensation lists for CARBOPLATIN KABI 10mg / ml Fresenius

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

104.90 RON

104.90 RON

0.00 RON

NHP 9.1 (C2) - Spinal cord transplant

Price

Copayment

Patient

104.90 RON

104.90 RON

0.00 RON